Economical and Organizational Impact of Adopting Different in Situ Hybridization Technologies to Assess HER2 Gene Amplification in Breast Cancer

Vincenzo Arena; D Paolini; R Rossoni; D Guardione

doi:10.1016/j.jval.2015.09.701

Economical and Organizational Impact of Adopting Different in Situ Hybridization Technologies to Assess HER2 Gene Amplification in Breast Cancer

Vincenzo Arena, D Paolini, R Rossoni, D Guardione

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Human epidermal growth factor receptor 2 (HER2) status identification is established by immunohistochemistry and in situ hybridisation (ISH). Silver in situ hybridisation (SISH) is an alternative technique to the fluorescence in situ hybridization (FISH). Both methods are recommended by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2013 guidelines. The primary aim of this analysis is to evaluate the economical and organizational impact by adopting FISH or SISH test for HER2 testing.

Lingua originale	English
pagine (da-a)	361-2-362
Rivista	Value in Health
Volume	18
DOI	https://doi.org/10.1016/j.jval.2015.09.701
Stato di pubblicazione	Pubblicato - 2015

Keywords

HER2,Economical

Accesso al documento

10.1016/j.jval.2015.09.701

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{7401ddd6c391412eb80577fda1be3fda,

title = "Economical and Organizational Impact of Adopting Different in Situ Hybridization Technologies to Assess HER2 Gene Amplification in Breast Cancer",

abstract = "Human epidermal growth factor receptor 2 (HER2) status identification is established by immunohistochemistry and in situ hybridisation (ISH). Silver in situ hybridisation (SISH) is an alternative technique to the fluorescence in situ hybridization (FISH). Both methods are recommended by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2013 guidelines. The primary aim of this analysis is to evaluate the economical and organizational impact by adopting FISH or SISH test for HER2 testing.",

keywords = "HER2,Economical, HER2,Economical",

author = "Vincenzo Arena and D Paolini and R Rossoni and D Guardione",

year = "2015",

doi = "10.1016/j.jval.2015.09.701",

language = "English",

volume = "18",

pages = "361--2--362",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Blackwell Science Incorporated:350 Main Street, Sixth Floor:Malden, MA 02148:(888)661-5800, (781)388-8250, EMAIL: csjournals@blacksci.com, INTERNET: http://www.blackwell-science.com, Fax: (781)388-8232",

}

TY - JOUR

T1 - Economical and Organizational Impact of Adopting Different in Situ Hybridization Technologies to Assess HER2 Gene Amplification in Breast Cancer

AU - Arena, Vincenzo

AU - Paolini, D

AU - Rossoni, R

AU - Guardione, D

PY - 2015

Y1 - 2015

N2 - Human epidermal growth factor receptor 2 (HER2) status identification is established by immunohistochemistry and in situ hybridisation (ISH). Silver in situ hybridisation (SISH) is an alternative technique to the fluorescence in situ hybridization (FISH). Both methods are recommended by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2013 guidelines. The primary aim of this analysis is to evaluate the economical and organizational impact by adopting FISH or SISH test for HER2 testing.

AB - Human epidermal growth factor receptor 2 (HER2) status identification is established by immunohistochemistry and in situ hybridisation (ISH). Silver in situ hybridisation (SISH) is an alternative technique to the fluorescence in situ hybridization (FISH). Both methods are recommended by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2013 guidelines. The primary aim of this analysis is to evaluate the economical and organizational impact by adopting FISH or SISH test for HER2 testing.

KW - HER2,Economical

UR - http://hdl.handle.net/10807/122889

U2 - 10.1016/j.jval.2015.09.701

DO - 10.1016/j.jval.2015.09.701

M3 - Article

VL - 18

SP - 361-2-362

JO - Value in Health

JF - Value in Health

SN - 1098-3015

ER -

Economical and Organizational Impact of Adopting Different in Situ Hybridization Technologies to Assess HER2 Gene Amplification in Breast Cancer

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo